Prostate-specific antigen: effect of pelvic irradiation

Radiology. 2000 Jun;215(3):757-60. doi: 10.1148/radiology.215.3.r00jn09757.

Abstract

Purpose: To study the effect of pelvic irradiation on the level of serum prostate-specific antigen (PSA).

Materials and methods: Of 33 patients treated with pelvic irradiation to the prostate and seminal vesicles for anal and rectal cancer, 26 received 50.4 Gy or more (1. 8 Gy per fraction), and seven received 25.0 Gy (5.0 Gy per fraction). PSA levels were measured before (n = 33), during (n = 26), and after radiation therapy (n = 33). In 24 patients, follow-up (mean, 15.7 months) PSA data were obtained. Actual and pretreatment PSA levels were compared (Wilcoxon rank test).

Results: During the first 3 weeks in all patients, PSA levels rose steeply, culminating in a 3. 7-fold increase (P =.02). At the end of radiation therapy (7 weeks), the PSA level was no longer significantly different from the pretreatment value. In the long term, the PSA level decreased to 77% of the pretreatment value (P =.04).

Conclusion: Irradiation of the prostate initially elevates serum PSA levels. Apparently PSA release is determined by the duration of radiation therapy, while the accumulated dose has a minor effect. In the long term, PSA production is impaired after radical radiation therapy. PSA reference concentrations should be adjusted to these reduced levels.

Publication types

  • Comparative Study

MeSH terms

  • Anus Neoplasms / blood
  • Anus Neoplasms / radiotherapy
  • Combined Modality Therapy
  • Follow-Up Studies
  • Humans
  • Male
  • Pelvis / radiation effects*
  • Prostate-Specific Antigen / blood
  • Prostate-Specific Antigen / radiation effects*
  • Radiotherapy Dosage
  • Rectal Neoplasms / blood
  • Rectal Neoplasms / radiotherapy
  • Statistics, Nonparametric
  • Time Factors

Substances

  • Prostate-Specific Antigen